Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism
Abstract
:1. Introduction
2. Deformation of the TTR Quaternary Structure
2.1. Conformational States of TTR Monomers
2.2. TTR Dimers
2.3. Oligomerization and Amyloid Formation
3. Proteolysis-Induced Aggregation of TTR
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Ingbar, S.H. Pre-albumin: A thyroxine-binding protein of human plasma. Endocrinology 1958, 63, 256–259. [Google Scholar] [CrossRef]
- Robbins, J.; Rall, J.E. Proteins associated with the thyroid hormones. Physiol. Rev. 1960, 40, 415–489. [Google Scholar] [CrossRef]
- Ingbar, S.H. Observations concerning the binding of thyroid hormones by human serum prealbumin. J. Clin. Investig. 1963, 42, 143–160. [Google Scholar] [CrossRef]
- Stabilini, R.; Vergani, C.; Agostoni, A.; Agostoni, R.P.V. Influence of age and sex on prealbumin levels. Clin. Chim. Acta 1968, 20, 358–359. [Google Scholar] [CrossRef]
- Schreiber, G.; Aldred, A.R.; Jaworowski, A.; Nilsson, C.; Achen, M.G.; Segal, M.B. Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am. J. Physiol. Integr. Comp. Physiol. 1990, 258, R338–R345. [Google Scholar] [CrossRef]
- Palha, J.A. Transthyretin as a thyroid hormone carrier: Function revisited. Clin. Chem. Lab. Med. 2002, 40, 1292–1300. [Google Scholar] [CrossRef] [PubMed]
- Kato, M.; Kato, K.; Blaner, W.S.; Chertow, B.S.; Goodman, D.S. Plasma and cellular retinoid-binding proteins and transthyretin (prealbumin) are all localized in the islets of Langerhans in the rat. Proc. Natl. Acad. Sci. USA 1985, 82, 2488–2492. [Google Scholar] [CrossRef] [Green Version]
- Pfeffer, B.A.; Becerra, S.P.; Borst, D.E.; Won, P. Expression of transthyretin and retinol binding protein mRNAs and secretion of transthyretin by cultured monkey retinal pigment epithelium. Mol. Vis. 2004, 10, 23–30. [Google Scholar] [PubMed]
- Blake, C.C.F.; Swan, I.D.A.; Rerat, C.; Berthou, J.; Laurent, A.; Rerat, B. An X-ray study of the subunit structure of prealbumin. J. Mol. Biol. 1971, 61, 217–224. [Google Scholar] [CrossRef]
- Blake, C.C.F.; Geisow, M.J.; Oatley, S.J.; Rérat, B.; Rérat, C. Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J. Mol. Biol. 1978, 121, 339–356. [Google Scholar] [CrossRef]
- Wojtczak, A.; Cody, V.; Luft, J.R.; Pangborn, W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 Å resolution. Acta Crystallogr. Sect. D Biol. Crystallogr. 1996, 52, 758–765. [Google Scholar] [CrossRef]
- Costa, P.P.; Figueira, A.S.; Bravo, F.R. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc. Natl. Acad. Sci. USA 1978, 75, 4499–4503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 1990, 87, 2843–2845. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coelho, T. Familial amyloid polyneuropathy: New developments in genetics and treatment. Curr. Opin. Neurol. 1996, 9, 355–359. [Google Scholar] [CrossRef]
- Jacobson, D.R.; Pastore, R.D.; Yaghoubian, R.; Kane, I.; Gallo, G.; Buck, F.S.; Buxbaum, J.N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 1997, 336, 466–473. [Google Scholar] [CrossRef] [PubMed]
- Connors, L.H.; Lim, A.; Prokaeva, T.; Roskens, V.A.; Costello, C.E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10, 160–184. [Google Scholar] [CrossRef]
- Jacobson, D.R.; Alexander, A.A.; Tagoe, C.; Buxbaum, J.N. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African–Americans. Amyloid 2015, 22, 171–174. [Google Scholar] [CrossRef] [PubMed]
- Buxbaum, J.N.; Ruberg, F.L. Transthyretin V122I (pV142I)* cardiac amyloidosis: An age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet. Med. 2017, 19, 733–742. [Google Scholar] [CrossRef] [Green Version]
- Akinboboye, O.; Shah, K.; Warner, A.L.; Damy, T.; Taylor, H.A.; Gollob, J.; Powell, C.; Karsten, V.; Vest, J.; Maurer, M.S. DISCOVERY: Prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid 2020, 27, 223–230. [Google Scholar] [CrossRef]
- Johnson, S.M.; Connelly, S.; Fearns, C.; Powers, E.T.; Kelly, J.W. The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. Biol. 2012, 421, 185–203. [Google Scholar] [CrossRef] [Green Version]
- Colon, W.; Kelly, J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31, 8654–8660. [Google Scholar] [CrossRef]
- Lai, Z.; Colón, W.; Kelly, J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35, 6470–6482. [Google Scholar] [CrossRef] [PubMed]
- Miroy, G.J.; Lai, Z.; Lashuel, H.A.; Peterson, S.A.; Strang, C.; Kelly, J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 1996, 93, 15051–15056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Razavi, H.; Palaninathan, S.K.; Powers, E.T.; Wiseman, R.L.; Purkey, H.E.; Mohamedmohaideen, N.N.; Deechongkit, S.; Chiang, K.P.; Dendle, M.T.A.; Sacchettini, J.C.; et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action. Angew. Chemie Int. Ed. 2003, 42, 2758–2761. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.M.; Wiseman, R.L.; Sekijima, Y.; Green, N.S.; Adamski-Werner, S.L.; Kelly, J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc. Chem. Res. 2005, 38, 911–921. [Google Scholar] [CrossRef]
- Bulawa, C.E.; Connelly, S.; DeVit, M.; Wang, L.; Weigel, C.; Fleming, J.A.; Packman, J.; Powers, E.T.; Wiseman, R.L.; Foss, T.R.; et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. USA 2012, 109, 9629–9634. [Google Scholar] [CrossRef] [Green Version]
- Le Bras, A. Tafamidis: A new treatment for ATTR cardiomyopathy. Nat. Rev. Cardiol. 2018, 15, 652. [Google Scholar] [CrossRef]
- Burton, A.; Castaño, A.; Bruno, M.; Riley, S.; Schumacher, J.; Sultan, M.B.; See Tai, S.; Judge, D.P.; Patel, J.K.; Kelly, J.W. Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Des. Devel. Ther. 2021, 15, 1225–1243. [Google Scholar] [CrossRef]
- Hörnberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-Eriksson, A.E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 2000, 302, 649–669. [Google Scholar] [CrossRef]
- Palaninathan, S.K. Nearly 200 X-ray crystal structures of transthyretin: What do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr. Med. Chem. 2012, 19, 2324–2342. [Google Scholar] [CrossRef]
- Zanotti, G.; Vallese, F.; Ferrari, A.; Menozzi, I.; Saldaño, T.E.; Berto, P.; Fernandez-Alberti, S.; Berni, R. Structural and dynamics evidence for scaffold asymmetric flexibility of the human transthyretin tetramer. PLoS ONE 2017, 12, e0187716. [Google Scholar] [CrossRef] [Green Version]
- Foss, T.R.; Wiseman, R.L.; Kelly, J.W. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 2005, 44, 15525–15533. [Google Scholar] [CrossRef]
- Mangione, P.P.; Porcari, R.; Gillmore, J.D.; Pucci, P.; Monti, M.; Porcari, M.; Giorgetti, S.; Marchese, L.; Raimondi, S.; Serpell, L.C.; et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc. Natl. Acad. Sci. USA 2014, 111, 1539–1544. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.H.; Oroz, J.; Zweckstetter, M. Structure of monomeric transthyretin carrying the clinically important T119M mutation. Angew. Chemie Int. Ed. 2016, 55, 16168–16171. [Google Scholar] [CrossRef] [Green Version]
- Oroz, J.; Kim, J.H.; Chang, B.J.; Zweckstetter, M. Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 2017, 24, 407–413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, X.; Smith, C.S.; Petrassi, H.M.; Hammarström, P.; White, J.T.; Sacchettini, J.C.; Kelly, J.W. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001, 40, 11442–11452. [Google Scholar] [CrossRef]
- Coelho, T.; Carvalho, M.; Saraiva, M.; Alves, C.; Almeida, M.; Costa, P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met30 and TTR Met119. J. Rheumatol. 1993, 20, 179. [Google Scholar]
- Hammarström, P.; Schneider, F.; Kelly, J.W. Trans-suppression of misfolding in an amyloid disease. Science 2001, 293, 2459–2462. [Google Scholar] [CrossRef] [PubMed]
- Lim, K.H.; Dyson, H.J.; Kelly, J.W.; Wright, P.E. Localized structural fluctuations promote amyloidogenic conformations in transthyretin. J. Mol. Biol. 2013, 425, 977–988. [Google Scholar] [CrossRef] [Green Version]
- Roche, J.; Royer, C.A.; Roumestand, C. Monitoring protein folding through high pressure NMR spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 2017, 102–103, 15–31. [Google Scholar] [CrossRef] [PubMed]
- Ferrão-Gonzales, A.O.; Souto, S.O.; Silva, J.L.; Foguel, D. The preaggregated state of an amyloidogenic protein: Hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proc. Natl. Acad. Sci. USA 2000, 97, 6445–6450. [Google Scholar] [CrossRef] [Green Version]
- Foguel, D.; Suarez, M.C.; Ferrão-Gonzales, A.D.; Porto, T.C.R.; Palmieri, L.; Einsiedler, C.M.; Andrade, L.R.; Lashuel, H.A.; Lansbury, P.T.; Kelly, J.W.; et al. Dissociation of amyloid fibrils of α-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc. Natl. Acad. Sci. USA 2003, 100, 9831–9836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palhano, F.L.; Leme, L.P.; Busnardo, R.G.; Foguel, D. Trapping the monomer of a non-amyloidogenic variant of transthyretin: Exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. J. Biol. Chem. 2009, 284, 1443–1453. [Google Scholar] [CrossRef] [Green Version]
- Gustavsson, Å.; Engström, U.; Westermark, P. Normal transthyretin and synthetic transthyretin fragments from amyloid-like fibrils in vitro. Biochem. Biophys. Res. Commun. 1991, 175, 1159–1164. [Google Scholar] [CrossRef]
- Liang, Y.; Ore, M.O.; Morin, S.; Wilson, D.J. Specific disruption of transthyretin(105-115) fibrilization using “stabilizing” inhibitors of transthyretin amyloidogenesis. Biochemistry 2012, 51, 3523–3530. [Google Scholar] [CrossRef]
- Fitzpatrick, A.W.P.; Debelouchina, G.T.; Bayro, M.J.; Clare, D.K.; Caporini, M.A.; Bajaj, V.S.; Jaroniec, C.P.; Wang, L.; Ladizhansky, V.; Müller, S.A.; et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc. Natl. Acad. Sci. USA 2013, 110, 5468–5473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Das, J.K.; Mall, S.S.; Bej, A.; Mukherjee, S. Conformational flexibility tunes the propensity of transthyretin to form fibrils through non-native intermediate states. Angew. Chemie Int. Ed. 2014, 53, 12781–12784. [Google Scholar] [CrossRef] [PubMed]
- Lim, K.H.; Dasari, A.K.R.; Hung, I.; Gan, Z.; Kelly, J.W.; Wemmer, D.E. Structural changes associated with transthyretin misfolding and amyloid formation revealed by solution and solid-state NMR. Biochemistry 2016, 55, 1941–1944. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jazaj, D.; Ghadami, S.A.; Bemporad, F.; Chiti, F. Probing conformational changes of monomeric transthyretin with second derivative fluorescence. Sci. Rep. 2019, 9, 10988. [Google Scholar] [CrossRef] [Green Version]
- Childers, M.C.; Daggett, V. Edge strand dissociation and conformational changes in transthyretin under amyloidogenic conditions. Biophys. J. 2020, 119, 1995–2009. [Google Scholar] [CrossRef]
- Saelices, L.; Johnson, L.M.; Liang, W.Y.; Sawaya, M.R.; Cascio, D.; Ruchala, P.; Whitelegge, J.; Jiang, L.; Riek, R.; Eisenberg, D.S. Uncovering the mechanism of aggregation of human transthyretin. J. Biol. Chem. 2015, 290, 28932–28943. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yokoyama, T.; Mizuguchi, M.; Nabeshima, Y.; Kusaka, K.; Yamada, T.; Hosoya, T.; Ohhara, T.; Kurihara, K.; Tomoyori, K.; Tanaka, I.; et al. Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin. J. Struct. Biol. 2012, 177, 283–290. [Google Scholar] [CrossRef] [PubMed]
- Yokoyama, T.; Hanawa, Y.; Obita, T.; Mizuguchi, M. Stability and crystal structures of His88 mutant human transthyretins. FEBS Lett. 2017, 591, 1862–1871. [Google Scholar] [CrossRef] [Green Version]
- Sun, X.; Dyson, H.J.; Wright, P.E. Fluorotryptophan incorporation modulates the structure and stability of transthyretin in a site-specific manner. Biochemistry 2017, 56, 5570–5581. [Google Scholar] [CrossRef] [PubMed]
- Daggett, V. α-sheet: The toxic conformer in amyloid diseases? Acc. Chem. Res. 2006, 39, 594–602. [Google Scholar] [CrossRef] [PubMed]
- Bi, T.M.; Daggett, V. The role of α-sheet in amyloid oligomer aggregation and toxicity. Yale J. Biol. Med. 2018, 91, 247–255. [Google Scholar]
- Armen, R.S.; Alonso, D.O.V.; Daggett, V. Anatomy of an amyloidogenic intermediate: Conversion of β-sheet to α-sheet structure in transthyretin at acidic pH. Structure 2004, 12, 1847–1863. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Steward, R.E.; Armen, R.S.; Daggett, V. Different disease-causing mutations in transthyretin trigger the same conformational conversion. Protein Eng. Des. Sel. 2008, 21, 187–195. [Google Scholar] [CrossRef] [Green Version]
- Childers, M.C.; Daggett, V. Drivers of α-sheet formation in transthyretin under amyloidogenic conditions. Biochemistry 2019, 58, 4408–4423. [Google Scholar] [CrossRef] [PubMed]
- Hopping, G.; Kellock, J.; Barnwal, R.P.; Law, P.; Bryers, J.; Varani, G.; Caughey, B.; Daggett, V. Designed α-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife 2014, 3, e01681. [Google Scholar] [CrossRef]
- Maris, N.L.; Shea, D.; Bleem, A.; Bryers, J.D.; Daggett, V. Chemical and physical variability in structural isomers of an L/D α-sheet peptide designed to inhibit amyloidogenesis. Biochemistry 2018, 57, 507–510. [Google Scholar] [CrossRef] [Green Version]
- Matsubara, K.; Mizuguchi, M.; Igarashi, K.; Shinohara, Y.; Takeuchi, M.; Matsuura, A.; Saitoh, T.; Mori, Y.; Shinoda, H.; Kawano, K. Dimeric transthyretin variant assembles into spherical neurotoxins. Biochemistry 2005, 44, 3280–3288. [Google Scholar] [CrossRef]
- Mizuguchi, M.; Yokoyama, T.; Nabeshima, Y.; Kawano, K.; Tanaka, I.; Niimura, N. Quaternary structure, aggregation and cytotoxicity of transthyretin. Amyloid 2012, 19, 5–7. [Google Scholar] [CrossRef] [PubMed]
- Dongmo Foumthuim, C.J.; Corazza, A.; Berni, R.; Esposito, G.; Fogolari, F. Dynamics and thermodynamics of transthyretin association from molecular dynamics simulations. Biomed. Res. Int. 2018, 7480749, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shirzadeh, M.; Boone, C.D.; Laganowsky, A.; Russell, D.H. Topological analysis of transthyretin disassembly mechanism: Surface-induced dissociation reveals hidden reaction pathways. Anal. Chem. 2019, 91, 2345–2351. [Google Scholar] [CrossRef] [PubMed]
- Olofsson, A.; Ippel, H.J.; Baranov, V.; Hörstedt, P.; Wijmenga, S.; Lundgren, E. Capture of a dimeric intermediate during transthyretin amyloid formation. J. Biol. Chem. 2001, 276, 39592–39599. [Google Scholar] [CrossRef] [Green Version]
- Dasari, A.K.R.; Hughes, R.M.; Wi, S.; Hung, I.; Gan, Z.; Kelly, J.W.; Lim, K.H. Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers. Sci. Rep. 2019, 9, 33. [Google Scholar] [CrossRef] [Green Version]
- Pires, R.H.; Saraiva, M.J.; Damas, A.M.; Kellermayer, M.S.Z. Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers. J. Mol. Recognit. 2017, 30, e2587. [Google Scholar] [CrossRef] [Green Version]
- Mendes Sousa, M.M.; Cardoso, I.; Fernandes, R.; Guimarães, A.; João Saraiva, M. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 2001, 159, 1993–2000. [Google Scholar] [CrossRef]
- Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J.W.; Buxbaum, J.N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA 2004, 101, 2817–2822. [Google Scholar] [CrossRef] [Green Version]
- Faria, T.Q.; Almeida, Z.L.; Cruz, P.F.; Jesus, C.S.H.; Castanheira, P.; Brito, R.M.M. A look into amyloid formation by transthyretin: Aggregation pathway and a novel kinetic model. Phys. Chem. Chem. Phys. 2015, 17, 7255–7263. [Google Scholar] [CrossRef] [PubMed]
- Pires, R.H.; Karsai, Á.; Saraiva, M.J.; Damas, A.M.; Kellermayer, M.S.Z. Distinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrils. PLoS ONE 2012, 7, e44992. [Google Scholar] [CrossRef]
- Pires, R.H.; Saraiva, M.J.; Damas, A.M.; Kellermayer, M.S.Z. Structure and assembly-disassembly properties of wild-type transthyretin amyloid protofibrils observed with atomic force microscopy. J. Mol. Recognit. 2011, 24, 467–476. [Google Scholar] [CrossRef] [PubMed]
- Frangolho, A.; Correia, B.E.; Vaz, D.C.; Almeida, Z.L.; Brito, R.M.M. Oligomerization profile of human transthyretin variants with distinct amyloidogenicity. Molecules 2020, 25, 5698. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, M.; Wiese, S.; Adak, V.; Engler, J.; Agarwal, S.; Fritz, G.; Westermark, P.; Zacharias, M.; Fändrich, M. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat. Commun. 2019, 10, 5008. [Google Scholar] [CrossRef] [Green Version]
- Lim, K.H.; Dasari, A.K.R.; Hung, I.; Gan, Z.; Kelly, J.W.; Wright, P.E.; Wemmer, D.E. Solid-state NMR studies reveal native-like β-sheet structures in transthyretin amyloid. Biochemistry 2016, 55, 5272–5278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lim, K.H.; Dasari, A.K.R.; Ma, R.; Hung, I.; Gan, Z.; Kelly, J.W.; Fitzgerald, M.C. Pathogenic mutations induce partial structural changes in the native β-sheet structure of transthyretin and accelerate aggregation. Biochemistry 2017, 56, 4808–4818. [Google Scholar] [CrossRef] [Green Version]
- Jaroniec, C.P.; MacPhee, C.E.; Bajaj, V.S.; McMahon, M.T.; Dobson, C.M.; Griffin, R.G. High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc. Natl. Acad. Sci. USA 2004, 101, 711–716. [Google Scholar] [CrossRef] [Green Version]
- Thylen, C.; Wahlqvist, J.; Haettner, E.; Sandgren, O.; Holmgren, G.; Lundgren, E. Modifications of transthyretin in amyloid fibrils: Analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J. 1993, 12, 743–748. [Google Scholar] [CrossRef] [PubMed]
- Hermansen, L.F.; Bergman, T.; Jörnvall, H.; Husby, G.; Ranløv, I.; Sletten, K. Purification and characterization of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy. Eur. J. Biochem. 1995, 227, 772–779. [Google Scholar] [CrossRef]
- Bergström, J.; Gustavsson, Å.; Hellman, U.; Sletten, K.; Murphy, C.L.; Weiss, D.T.; Solomon, A.; Olofsson, B.O.; Westermark, P. Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology. J. Pathol. 2005, 206, 224–232. [Google Scholar] [CrossRef]
- Kingsbury, J.S.; Théberge, R.; Karbassi, J.A.; Lim, A.; Costello, C.E.; Connors, L.H. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry. Anal. Chem. 2007, 79, 1990–1998. [Google Scholar] [CrossRef] [PubMed]
- Yee, A.W.; Aldeghi, M.; Blakeley, M.P.; Ostermann, A.; Mas, P.J.; Moulin, M.; de Sanctis, D.; Bowler, M.W.; Mueller-Dieckmann, C.; Mitchell, E.P.; et al. A molecular mechanism for transthyretin amyloidogenesis. Nat. Commun. 2019, 10, 925. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marcoux, J.; Mangione, P.P.; Porcari, R.; Degiacomi, M.T.; Verona, G.; Taylor, G.W.; Giorgetti, S.; Raimondi, S.; Sanglier-Cianférani, S.; Benesch, J.L.; et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol. Med. 2015, 7, 1337–1349. [Google Scholar] [CrossRef]
- Klimtchuk, E.S.; Prokaeva, T.; Frame, N.M.; Abdullahi, H.A.; Spencer, B.; Dasari, S.; Cui, H.; Berk, J.L.; Kurtin, P.J.; Connors, L.H.; et al. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proc. Natl. Acad. Sci. USA 2018, 115, E6428–E6436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dasari, A.K.R.; Arreola, J.; Michael, B.; Griffin, R.G.; Kelly, J.W.; Lim, K.H. Disruption of the CD loop by enzymatic cleavage promotes the formation of toxic transthyretin oligomers through a common transthyretin misfolding pathway. Biochemistry 2020, 59, 2319–2327. [Google Scholar] [CrossRef] [PubMed]
- Peterle, D.; Pontarollo, G.; Spada, S.; Brun, P.; Palazzi, L.; Sokolov, A.V.; Spolaore, B.; Polverino de Laureto, P.; Vasilyev, V.B.; Castagliuolo, I.; et al. A serine protease secreted from Bacillus subtilis cleaves human plasma transthyretin to generate an amyloidogenic fragment. Commun. Biol. 2020, 3, 764. [Google Scholar] [CrossRef]
- Mangione, P.P.; Verona, G.; Corazza, A.; Marcoux, J.; Canetti, D.; Giorgetti, S.; Raimondi, S.; Stoppini, M.; Esposito, M.; Relini, A.; et al. Plasminogen activation triggers transthyretin amyloidogenesis in vitro. J. Biol. Chem. 2018, 293, 14192–14199. [Google Scholar] [CrossRef] [Green Version]
- Kolstoe, S.E.; Mangione, P.P.; Bellotti, V.; Taylor, G.W.; Tennent, G.A.; Deroo, S.; Morrison, A.J.; Cobb, A.J.A.; Coyne, A.; McCammon, M.G.; et al. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc. Natl. Acad. Sci. USA 2010, 107, 20483–20488. [Google Scholar] [CrossRef] [Green Version]
- Corazza, A.; Verona, G.; Waudby, C.A.; Mangione, P.P.; Bingham, R.P.; Uings, I.; Canetti, D.; Nocerino, P.; Taylor, G.W.; Pepys, M.B.; et al. Binding of monovalent and bivalent ligands by transthyretin causes different short- and long-distance conformational changes. J. Med. Chem. 2019, 62, 8274–8283. [Google Scholar] [CrossRef] [Green Version]
- Ferguson, R.N.; Edelhoch, H.; Saroff, H.A.; Robbins, J.; Cahnmann, H.J. Negative cooperativity in the binding of thyroxine to human serum prealbumin. Biochemistry 1975, 14, 282–289. [Google Scholar] [CrossRef] [PubMed]
- Florio, P.; Folli, C.; Cianci, M.; Del Rio, D.; Zanotti, G.; Berni, R. Transthyretin binding heterogeneity and antiamyloidogenic activity of natural polyphenols and their metabolites. J. Biol. Chem. 2015, 290, 29769–29780. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, K.; Kelly, J.W.; Wemmer, D.E. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. J. Mol. Biol. 2002, 320, 821–832. [Google Scholar] [CrossRef]
- Liu, Y.T.; Yen, Y.J.; Ricardo, F.; Chang, Y.; Wu, P.H.; Huang, S.J.; Lin, K.P.; Yu, T.Y. Biophysical characterization and modulation of Transthyretin Ala97Ser. Ann. Clin. Transl. Neurol. 2019, 6, 1961–1970. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bezerra, F.; Saraiva, M.J.; Almeida, M.R. Modulation of the mechanisms driving transthyretin amyloidosis. Front. Mol. Neurosci. 2020, 13, 592644. [Google Scholar] [CrossRef]
- Leach, B.I.; Zhang, X.; Kelly, J.W.; Dyson, H.J.; Wright, P.E. NMR measurements reveal the structural basis of transthyretin destabilization by pathogenic mutations. Biochemistry 2018, 57, 4421–4430. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Jane Dyson, H.; Wright, P.E. Kinetic analysis of the multistep aggregation pathway of human transthyretin. Proc. Natl. Acad. Sci. USA 2018, 115, E6201–E6208. [Google Scholar] [CrossRef] [Green Version]
- Saelices, L.; Chung, K.; Lee, J.H.; Cohn, W.; Whitelegge, J.P.; Benson, M.D.; Eisenberg, D.S. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc. Natl. Acad. Sci. USA 2018, 115, E6741–E6750. [Google Scholar] [CrossRef] [Green Version]
- Groenning, M.; Campos, R.I.; Hirschberg, D.; Hammarström, P.; Vestergaard, B. Considerably unfolded transthyretin monomers preceed and exchange with dynamically structured amyloid protofibrils. Sci. Rep. 2015, 5, 11443. [Google Scholar] [CrossRef] [Green Version]
- Miyata, M.; Sato, T.; Kugimiya, M.; Sho, M.; Nakamura, T.; Ikemizu, S.; Chirifu, M.; Mizuguchi, M.; Nabeshima, Y.; Suwa, Y.; et al. The Crystal Structure of the Green Tea Polyphenol (−)-Epigallocatechin Gallate−Transthyretin Complex Reveals a Novel Binding Site Distinct from the Thyroxine Binding Site. Biochemistry 2010, 49, 6104–6114. [Google Scholar] [CrossRef]
- Ferreira, N.; Pereira-Henriques, A.; Almeida, M.R. Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors. Biochem. Biophys. Rep. 2015, 3, 123–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ortore, G.; Orlandini, E.; Braca, A.; Ciccone, L.; Rossello, A.; Martinelli, A.; Nencetti, S. Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds. ChemMedChem 2016, 11, 1865–1874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quintas, A.; Vaz, D.C.; Cardoso, I.; Saraiva, M.J.M.; Brito, R.M.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 2001, 276, 27207–27213. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Si, J.-B.; Kim, B.; Kim, J.H. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism. Int. J. Mol. Sci. 2021, 22, 4429. https://doi.org/10.3390/ijms22094429
Si J-B, Kim B, Kim JH. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism. International Journal of Molecular Sciences. 2021; 22(9):4429. https://doi.org/10.3390/ijms22094429
Chicago/Turabian StyleSi, Jin-Beom, Bokyung Kim, and Jin Hae Kim. 2021. "Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism" International Journal of Molecular Sciences 22, no. 9: 4429. https://doi.org/10.3390/ijms22094429